Glycomine is a biotechnology company developing therapies for rare diseases, specifically targeting PMM2-CDG with its investigational drug GLM101.

Immunis, Inc. is a biotech company developing stem cell-derived biologics to treat age-related muscle atrophy and metabolic dysfunction.